Literature DB >> 22631037

Hypercoagulability in non-transfusion-dependent thalassemia.

Maria D Cappellini1, Khaled M Musallam, Erika Poggiali, Ali T Taher.   

Abstract

Beta (β)-thalassemia is characterized by a hypercoagulable state and an increased risk of thrombosis, which can result in significant morbidity and mortality. The molecular and cellular mechanisms contributing to hypercoagulability are diverse and include chronic platelet activation, alteration of red blood cell membranes, abnormal expression of adhesion molecules on vascular endothelial cells, and dysregulation of hemostasis. Regular transfusions decrease the risk of thrombosis, whereas splenectomy significantly increases the risk. Splenectomized adults with non-transfusion-dependent thalassemia are also at high risk for ischemic brain damage. Strategies to lower the risk of thrombosis should be considered, including transfusion therapy to raise hemoglobin levels and avoidance or delay of splenectomy.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22631037     DOI: 10.1016/S0268-960X(12)70007-3

Source DB:  PubMed          Journal:  Blood Rev        ISSN: 0268-960X            Impact factor:   8.250


  16 in total

1.  Thalassaemia intermedia: the role of erythroexchange in the treatment of an indolent wound.

Authors:  Marco Pignatti; Maurizio Govoni; Giuseppe Graldi; Lucrezia Pacchioni; Giorgio De Santis; Caterina Borgna
Journal:  Blood Transfus       Date:  2013-11-14       Impact factor: 3.443

Review 2.  Thalassemia and Moyamoya syndrome: unfurling an intriguing association.

Authors:  Shambaditya Das; Souvik Dubey; Mrinal Acharya; Subhankar Chatterjee; Durjoy Lahiri; Goutam Das; Biman Kanti Ray; Markus Kraemer
Journal:  J Neurol       Date:  2019-08-17       Impact factor: 4.849

Review 3.  Management of non-transfusion-dependent thalassemia: a practical guide.

Authors:  Ali T Taher; Maria Domenica Cappellini
Journal:  Drugs       Date:  2014-10       Impact factor: 9.546

4.  Quantitative proteomics of plasma vesicles identify novel biomarkers for hemoglobin E/β-thalassemic patients.

Authors:  Janejira Kittivorapart; Vanja Karamatic Crew; Marieangela C Wilson; Kate J Heesom; Noppadol Siritanaratkul; Ashley M Toye
Journal:  Blood Adv       Date:  2018-01-23

5.  A systematic review of quality of life in sickle cell disease and thalassemia after stem cell transplant or gene therapy.

Authors:  Sherif M Badawy; Usman Beg; Robert I Liem; Sonali Chaudhury; Alexis A Thompson
Journal:  Blood Adv       Date:  2021-01-26

6.  Platelet haemostatic properties in β-thalassaemia: the effect of blood transfusion.

Authors:  Alice Trinchero; Marina Marchetti; Cinzia Giaccherini; Carmen J Tartari; Laura Russo; Anna Falanga
Journal:  Blood Transfus       Date:  2016-10-04       Impact factor: 3.443

Review 7.  β-Thalassemia intermedia: a comprehensive overview and novel approaches.

Authors:  Chingiz Asadov; Zohra Alimirzoeva; Tahira Mammadova; Gunay Aliyeva; Shahla Gafarova; Jeyhun Mammadov
Journal:  Int J Hematol       Date:  2018-01-29       Impact factor: 2.490

Review 8.  Non-transfusion-dependent thalassemias.

Authors:  Khaled M Musallam; Stefano Rivella; Elliott Vichinsky; Eliezer A Rachmilewitz
Journal:  Haematologica       Date:  2013-06       Impact factor: 9.941

Review 9.  Novel approach to reactive oxygen species in nontransfusion-dependent thalassemia.

Authors:  Paul I Tyan; Amr H Radwan; Assaad Eid; Anthony G Haddad; David Wehbe; Ali T Taher
Journal:  Biomed Res Int       Date:  2014-07-09       Impact factor: 3.411

10.  Prevalence and Risk Factors for Complications in Patients with Nontransfusion Dependent Alpha- and Beta-Thalassemia.

Authors:  Poramed Winichakoon; Adisak Tantiworawit; Thanawat Rattanathammethee; Sasinee Hantrakool; Chatree Chai-Adisaksopha; Ekarat Rattarittamrong; Lalita Norasetthada; Pimlak Charoenkwan
Journal:  Anemia       Date:  2015-11-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.